Molecular and functional assessment of the neurotransmitter receptors and their intracellular signaling pathways in post-mortem human brain from subjects with a diagnostic of major depression, schizophrenia, drug abuse or other neuropsychiatric disorders.
Evaluation of neuro-receptors in human glial tumors.
Study of the constitutive activity of neurotransmitter receptors and analysis of the inverse agonist properties of different drugs.
In vivo study of the long-term mechanism of action of the antidepressant and antipsychotic drugs.
Enhancement and acceleration of the antidepressant effect of drugs in animal models.
Role of epigenetic alterations induced by long-term treatment with psychoactive drugs.
Pharmacological screening of new molecules with potential antidepressant or antipsychotic effect.
Monitoring of brain levels of psychoactive drugs and the relation with the response rate to treatment.
Search of new diagnostic markers and therapeutic targets for psychiatric diseases by means of functional genomics and proteomics.
Molecular, biochemical and behavioural assessment of transgenic, neurodevelopmental or pharmacological animal models of neuropsychiatric disorders.
Study of the genetic polymorphisms related with suicidal behaviour.
Neurobiological basis of positive, negative and cognitive symptoms in schizophrenia.
Treatment of cognitive impairment associated to schizophrenia.
Etiopathogenic role of neuroinflammation in psychiatric diseases. Mechanisms of psychiatric symptoms in inflammatory diseases.
Identification of trait and status peripheral biomarkers in mental illness.
Design and evaluation of technological devices for cognitive evaluation.
